For the quarter ending 2026-03-31, GYRE had $431K increase in cash & cash equivalents over the period. $3,002K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Gyre Pharmaceuticals | 22,519 | - | - | - |
| Gyre | 0 | - | - | - |
| All Other Segments | 0 | - | - | - |
| Revenues | 22,519 | - | - | - |
| Gyre Pharmaceuticals | 1,227 | - | - | - |
| Gyre | 0 | - | - | - |
| All Other Segments | 0 | - | - | - |
| Cost of revenues | 1,227 | - | - | - |
| Gyre Pharmaceuticals | 14,136 | - | - | - |
| Gyre | 0 | - | - | - |
| All Other Segments | 0 | - | - | - |
| Selling and marketing | 14,136 | - | - | - |
| Research and development | 6,738 | - | - | - |
| General and administrative | 7,220 | - | - | - |
| Gyre Pharmaceuticals | 0 | - | - | - |
| Gyre | 2,553 | - | - | - |
| All Other Segments | 0 | - | - | - |
| Transaction costs | 2,553 | - | - | - |
| Total operating expenses | 31,874 | - | - | - |
| (loss) income from operations | -9,355 | - | - | - |
| Gyre Pharmaceuticals | 0 | - | - | - |
| Gyre | -89 | - | - | - |
| All Other Segments | 0 | - | - | - |
| Change in fair value of warrant liability | -89 | - | - | - |
| Gyre Pharmaceuticals | -162 | - | - | - |
| Gyre | 191 | - | - | - |
| All Other Segments | 0 | - | - | - |
| Other (expense) income, net | 29 | - | - | - |
| Gyre Pharmaceuticals | 621 | - | - | - |
| Gyre | 0 | - | - | - |
| All Other Segments | 0 | - | - | - |
| Income tax expense | 621 | - | - | - |
| Net (loss) income | -9,858 | -1,366 | 5,936 | 5,310 |
| Operating lease liabilities | - | -236 | -236 | -272 |
| Accrued interest on certificates of deposit | - | - | 267 | -189 |
| Accrued interest on bank deposit | - | -28 | - | - |
| Net proceeds from cvr liability settlement | - | 0 | 0 | 25 |
| Change in fair value of receivables from gcbp | - | 0 | 0 | 39 |
| Accounts and note receivables | - | - | - | 4,966 |
| Change in fair value of derivative liabilities | - | 0 | 0 | 39 |
| Stock-based compensation | 2,583 | 4,597 | 1,147 | 1,413 |
| Equity in loss of unconsolidated affiliate | -21 | -20 | -19 | -38 |
| Depreciation and amortization | 672 | 656 | 649 | 1,176 |
| Noncash lease expense | 217 | 171 | 206 | 400 |
| Amortization of land use rights | - | 39 | - | - |
| Deferred income taxes, net | -738 | -87 | -531 | -491 |
| Bad debt expense and other non-cash items | 195 | -34 | -54 | 25 |
| Accrued interest on long-term certificates of deposit | -647 | - | - | - |
| Change in fair value of warrant liability | -89 | -263 | 23 | -2,467 |
| Loss on disposal of property and equipment | -16 | -2 | -1 | -1 |
| Notes receivable | -1,902 | 4,848 | 178 | -3,879 |
| Accounts receivable | -8,573 | 4,825 | 5,981 | - |
| Inventories | 1,015 | 1,208 | -72 | 2,495 |
| Prepaid assets and other current assets | 912 | 509 | -398 | 95 |
| Income tax payable | 144 | 261 | 1,536 | -1,753 |
| Accounts payable | 139 | -433 | 483 | -37 |
| Other noncurrent liabilities | - | -47 | - | - |
| Due to related parties | - | -1 | - | - |
| Accrued expenses and other liabilities | 683 | 2,380 | -3,513 | 2,079 |
| Net cash (used in) provided by operating activities | 3,180 | -5,635 | 4,676 | 1,959 |
| Purchase of short-term investments | - | - | 564 | - |
| Acquisition of intangible assets | 5 | -4 | 15 | 722 |
| Purchase of certificates of deposit | 12,951 | 2,826 | 0 | 11,184 |
| Purchase of property and equipment | 178 | 144 | 668 | 378 |
| Proceeds from sale of equipment | 6 | 11 | 0 | 19 |
| Proceeds from the issuance of common stock-Two Thousand Twenty Four ATMProgram | - | - | 0 | 509 |
| Maturity of certificates of deposit | 10,073 | 4,239 | 0 | 11,190 |
| Proceeds from the issuance of common stock-May Two Thousand Twenty Five Underwritten Public Offering | - | - | 0 | 23,000 |
| Net cash (used in) provided by investing activities | -3,055 | 1,848 | -1,247 | -1,075 |
| Offering costs paid | - | - | -315 | 1,802 |
| Proceeds from the exercise of stock options | -2,017 | - | 50 | 1,988 |
| Net cash provided by financing activities | 21 | 318 | 365 | 23,695 |
| Effect of exchange rate changes on cash | 285 | 127 | 117 | 99 |
| Net increase in cash | 431 | -3,332 | 3,911 | 24,678 |
| Cash at beginning of the period | 37,070 | 40,402 | 11,813 | - |
| Cash at end of period | 37,501 | 37,070 | 40,402 | - |
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)